Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Autor:	Robert Bermel, Hans-Peter Hartung, Bruno Brochet, Ralph Benedict, Thomas Berger, William Carroll, Timothy Vollmer, Trygve Holmoy, Rana Karabudak, Joep Killestein, Carlos Nos, Francesco Patti, Amy Perrin Ross, Ludo Vanopdenbosch, Jens Wuerfel, Thomas Kuenzel, Karen Kadner, Inessa Kulyk, Mark Freedman
Rok vydání:	2023
Zdroj:	Thursday, April 27.
DOI:	10.1212/wnl.0000000000202202
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8348f93332d8b2f06492274a34ecfc59 https://doi.org/10.1212/wnl.0000000000202202 Zobrazit plný text záznamu